- Previous Close
0.5200 - Open
0.5300 - Bid 0.4500 x --
- Ask 0.5300 x --
- Day's Range
0.5200 - 0.5400 - 52 Week Range
0.1900 - 0.6950 - Volume
55,900 - Avg. Volume
66,786 - Market Cap (intraday)
114.537M - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.80
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. In addition, it provides Sunrise, a bio-signal to diagnose sleep apnea. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
somnomed.com/au/Recent News: SOM.AX
View MorePerformance Overview: SOM.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SOM.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SOM.AX
View MoreValuation Measures
Market Cap
114.54M
Enterprise Value
101.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.88
Price/Book (mrq)
2.41
Enterprise Value/Revenue
1.02
Enterprise Value/EBITDA
33.00
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.98%
Return on Assets (ttm)
-2.14%
Return on Equity (ttm)
-15.51%
Revenue (ttm)
100.25M
Net Income Avi to Common (ttm)
-6M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
18.5M
Total Debt/Equity (mrq)
12.45%
Levered Free Cash Flow (ttm)
923.07k